Stockscreener 앱 받기
3.70
14.35%
-0.62
시간 외 거래:
3.65
-0.05
-1.35%
전일 마감가:
$4.32
열려 있는:
$3.91
하루 거래량:
2.11M
Relative Volume:
0.94
시가총액:
$370.42M
수익:
$14.79M
순이익/손실:
$-102.44M
주가수익비율:
-1.2171
EPS:
-3.04
순현금흐름:
$-91.73M
1주 성능:
-22.59%
1개월 성능:
-33.81%
6개월 성능:
-46.92%
1년 성능:
-72.22%
1일 변동 폭
$3.5001
$4.05
1주일 범위
$3.5001
$4.86
52주 변동 폭
$2.88
$13.47
솔리드 바이오 Stock (SLDB) Company Profile
명칭
Solid Biosciences Inc
전화
617-337-4680
주소
500 RUTHERFORD AVENUE, CHARLESTOWN, MA
SLDB을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SLDB
Solid Biosciences Inc
|
3.70 | 370.42M | 14.79M | -102.44M | -91.73M | -3.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
솔리드 바이오 Stock (SLDB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-01-08 | 개시 | Truist | Buy |
| 2024-12-13 | 개시 | Wedbush | Outperform |
| 2024-12-10 | 개시 | JMP Securities | Mkt Outperform |
| 2024-07-15 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2024-06-24 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-05-31 | 재개 | Piper Sandler | Overweight |
| 2024-03-28 | 개시 | William Blair | Outperform |
| 2024-03-15 | 개시 | Citigroup | Buy |
| 2024-03-14 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2023-12-08 | 개시 | H.C. Wainwright | Buy |
| 2021-07-12 | 개시 | Piper Sandler | Neutral |
| 2021-05-27 | 개시 | Jefferies | Buy |
| 2021-03-16 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2021-03-09 | 개시 | Barclays | Overweight |
| 2021-01-08 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2020-07-28 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2020-05-07 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2019-10-11 | 개시 | Evercore ISI | Outperform |
| 2019-08-29 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2019-08-19 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-08-16 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2019-05-14 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2019-05-14 | 다운그레이드 | Goldman | Neutral → Sell |
| 2019-02-08 | 업그레이드 | Citigroup | Sell → Neutral |
| 2019-02-08 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2018-11-06 | 개시 | Citigroup | Sell |
| 2018-09-06 | 개시 | Credit Suisse | Neutral |
모두보기
솔리드 바이오 주식(SLDB)의 최신 뉴스
Sarepta safety update on Elevidys boosts Regenxbio, hurts Solid Bio - MSN
Solid Biosciences Inc.'s (NASDAQ:SLDB) market cap dropped US$53m last week; Private equity firms bore the brunt - simplywall.st
Regenxbio stock up, Solid Bio down post Sarepta update (RGNX) - Seeking Alpha
Solid Biosciences Inc. (SLDB): Among Top Insider Purchases Last Month - Insider Monkey
Solid Biosciences director Kahn Clare buys $9,924 in stock - Investing.com India
Solid Biosciences director Kahn Clare buys $9,924 in stock By Investing.com - Investing.com Australia
Solid Biosciences’ SWOT analysis: gene therapy firm’s stock poised for growth - Investing.com Australia
Solid Biosciences’ SWOT analysis: gene therapy firm’s stock poised for growth By Investing.com - Investing.com South Africa
Solid Biosciences Inc. (NASDAQ:SLDB) Receives Consensus Rating of “Buy” from Brokerages - Defense World
Solid Biosciences Inc. (NASDAQ:SLDB) Short Interest Update - Defense World
Q1 EPS Forecast for Solid Biosciences Boosted by Analyst - Defense World
Top 10 Insider Purchases Last Month - Insider Monkey
Solid Biosciences to Present at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference - GlobeNewswire
Solid Biosciences Inc. to Present Phase 1/2 INSPIRE DUCHENNE Trial Data on SGT-003 Gene Therapy for Duchenne Muscular Dystrophy at 2025 MDA Conference - Nasdaq
Breakthrough DMD Gene Therapy Results: Solid Bio Reveals INSPIRE Trial Data at Major Conference - StockTitan
Solid Biosciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Solid Biosciences Inc. (NASDAQ:SLDB) Shares Acquired by Rhumbline Advisers - Defense World
HC Wainwright Issues Positive Forecast for Solid Biosciences (NASDAQ:SLDB) Stock Price - Defense World
Solid Biosciences shares leap on raised price target to $20 By Investing.com - Investing.com Canada
Solid Biosciences price target raised to $20 from $16 at H.C. Wainwright - TipRanks
FY2026 Earnings Forecast for SLDB Issued By William Blair - Defense World
Chardan Capital Reaffirms “Buy” Rating for Solid Biosciences (NASDAQ:SLDB) - Defense World
SLDB Stock Rallies 60% in a Month: Here's What You Should Know - MSN
Wall Street Analysts Believe Solid Biosciences (SLDB) Could Rally 198.18%: Here's is How to Trade - Yahoo Finance
Solid Biosciences Inc expected to post a loss of 60 cents a shareEarnings Preview - TradingView
Solid Biosciences stock target holds at $15 on therapy optimism - Investing.com
Solid Biosciences: Promising Gene Therapy Advancements and Strategic Pipeline Expansion Justify Buy Rating - TipRanks
Solid Biosciences: Positive DMD Program Developments and Strong Financial Position Justify Buy Rating - TipRanks
Solid Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates - GlobeNewswire
Solid Biosciences Inc. (SLDB) reports earnings - Quartz
Solid Biosciences reports Q4 EPS ($1.00), consensus (78c) - TipRanks
Solid Biosciences Reports Positive Data from Duchenne Gene Therapy Trial and Provides Business Update - Nasdaq
Solid Biosciences Inc. SEC 10-K Report - TradingView
SLDBSolid Bioscience Latest Stock News & Market Updates - Stock Titan
Duchenne Patient Stories - Solid Biosciences
Solid Biosciences to Participate at Upcoming Investor Conferences - GlobeNewswire
Genetic Medicine Developer Solid Biosciences Sets March Conference Schedule: What's Coming? - StockTitan
Solid Biosciences (SLDB) Expected to Announce Quarterly Earnings on Wednesday - Defense World
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Is Solid Biosciences Inc. (SLDB) Among Stocks With At Least $20 Million In Insider Spending Recently? - Insider Monkey
How Solid Biosciences Uses Equity Compensation to Attract New Talent - StockTitan
10 Stocks With At Least $20 Million In Insider Spending Recently - Insider Monkey
3 Reasons to Sell CSL and 1 Stock to Buy Instead - The Globe and Mail
Solid Biosciences Inc. (SLDB) Latest Stock News & Headlines - Yahoo Canada Finance
Leerink Partnrs Issues Optimistic Outlook for SLDB Earnings - MarketBeat
Solid Biosciences Inc.'s (NASDAQ:SLDB) stock price dropped 11% last week; individual investors would not be happy - Yahoo Finance
3 Beaten-Down Biotech Stocks to Buy Before They Soar. Wall Street Is Predicting Jumps of 68% to 250%. - The Globe and Mail
What is Chardan Capital's Forecast for SLDB FY2025 Earnings? - MarketBeat
Solid Biosciences Inc [SLDB] stock for 4,030,000 USD was bought by Bain Capital Life Sciences Inv - Knox Daily
솔리드 바이오 (SLDB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.05%
1.79%
자본화:
|
볼륨(24시간):